Novo Integrated Sciences, Inc.
NVOS · OTC
8/31/2024 | 8/31/2023 | 8/31/2022 | 8/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.01 | -0.00 | 0.65 |
| FCF Yield | -40.40% | -16.11% | -12.53% | -2.84% |
| EV / EBITDA | -0.95 | -3.13 | -2.64 | -19.56 |
| Quality | ||||
| ROIC | -40.13% | -28.16% | -26.25% | -7.24% |
| Gross Margin | 43.20% | 39.39% | 40.89% | 41.08% |
| Cash Conversion Ratio | 0.17 | 0.17 | 0.18 | 0.23 |
| Growth | ||||
| Revenue 3-Year CAGR | 4.24% | 10.55% | 14.30% | -0.41% |
| Free Cash Flow Growth | 0.00% | 62.26% | -374.28% | -182.23% |
| Safety | ||||
| Net Debt / EBITDA | -0.38 | -0.69 | -0.48 | -2.10 |
| Interest Coverage | 12.74 | -1.67 | -1.27 | -25.90 |
| Efficiency | ||||
| Inventory Turnover | 7.55 | 6.88 | 7.89 | 16.15 |
| Cash Conversion Cycle | -21.48 | -72.71 | -16.82 | 15.61 |